Population pharmacokinetics of recombinant factor VIII: The relationships of pharmacokinetics to age and body weight

Blood

Volumn 119, Issue 2, 2012, Pages 612-618

  Björkman, Sven ^a   Oh, MyungShin ^b   Spotts, Gerald ^b   Schroth, Phillip ^b   Fritsch, Sandor ^c   Ewenstein, Bruce M ^b   Casey, Kathleen ^b   Fischer, Kathelijn ^d   Blanchette, Victor S ^e,f   Collins, Peter W ^g  

^a UPPSALA UNIVERSITY   (Sweden)

^b BAXTER HEALTHCARE CORPORATION   (United States)

^c BAXTER INNOVATIONS GMBH   (Austria)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CHILD; DISEASE SEVERITY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; HEMOPHILIA A; HUMAN; INFANT; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

EID: 84855853759     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-07-360594     Document Type: Article

References (30)

1. Collins PW, Björkman S, Fischer K, et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe haemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost. 2010;8(2):269-275.
2. Collins PW, Fischer K, Morfini M, Blanchette VS, Björkman S. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia. 2011; 17(1):2-10.
3. Aronstam A, McLellan DS,Wassef M, Mbatha PS. Effect of height and weight on the in vivo recovery of transfused factor VIII C. J Clin Pathol. 1982; 35(3):289-291. (Pubitemid 12153620)
4. Matucci M, Messori A, Donati-Cori G, et al. Kinetic evaluation of four factor VIII concentrates by model-independent methods. Scand J Haematol. 1985;34(1):22-28. (Pubitemid 15192981)
5. Björkman S, Carlsson M, Berntorp E, Stenberg P. Pharmacokinetics of factor VIII in humans: obtaining clinically relevant data from comparative studies. Clin Pharmacokinet. 1992;22(5):385-395.
6. Carlsson M, Berntorp E, Björkman S, Lethagen S, Ljung R. Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A. Haemophilia. 1997; 3(2):96-101. (Pubitemid 27187173)
7. Björkman S, Berntorp E. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokinet. 2001; 40(11):815-832. (Pubitemid 33095998)
8. Björkman S. Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective. Haemophilia. 2003;9(suppl 1):101-110. (Pubitemid 36622057)
9. van Dijk K, van der Bom JG, Lenting PJ, et al. Factor VIII half-life and clinical phenotype of severe hemophilia A. Haematologica. 2005;90(4): 494-498. (Pubitemid 40592892)
10. Barnes C, Lillicrap D, Pazmino-Canizares J, et al. Pharmacokinetics of recombinant factor VIII (Kogenate-FS) in children and causes of interpatient pharmacokinetic variability. Haemophilia. 2006;12(suppl 4):40-49. (Pubitemid 44404838)
11. Blanchette VS, Shapiro AD, Liesner RJ, et al. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost. 2008;6(8):1319-1326. (Pubitemid 352016311)
12. Björkman S, Folkesson A, Jönsson S. Pharmacokinetics and dose requirements of factor VIII over the age range of 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A. Eur J Clin Pharmacol. 2009;65(10):989-998.
13. Björkman S, Blanchette VS, Fischer K, et al. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. J Thromb Haemost. 2010;8(4):730-736.
14. Sheiner LB. The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. Drug Metab Rev. 1984; 15(1):153-171. (Pubitemid 14123936)
15. Aarons L. Population pharmacokinetics: theory and practice. Br J Clin Pharmacol. 1991;32(6): 669-670.
16. Stass H. Determination of minimal sampling time points for reliable pharmacokinetic evaluation of recombinant factor VIII: an exploratory population pharmacokinetic analysis in paediatric patients suffering from severe haemophilia. Haemophilia. 2006;12(suppl 4):50-55. (Pubitemid 44404839)
17. Bolon-Larger M, Chamouard V, Bressolle F, Boulieu R. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A. Ther Drug Monit. 2007;29(1):20-26. (Pubitemid 46279872)
18. Björkman S. Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A. Haemophilia. 2010; 16(4):597-605.
19. Björkman S. Evaluation of the TCIWorks Bayesian computer program for estimation of individual pharmacokinetics of FVIII. Haemophilia. 2011; 17(1):e239-e240.
20. Tarantino MD, Collins PW, Hay CRM, et al. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia. 2004;10(5):428-437. (Pubitemid 39328049)
21. Lee ML, Poon WY, Kingdon HS. A two-phase linear regression model for biologic half-life data. J Lab Clin Med. 1990;115(6):745-748. (Pubitemid 20213166)
22. Lee M, Morfini M, Schulman S, et al. The design and analysis of pharmacokinetic studies of coagulation factors. http://www.isth.org/ Publications/OfficialCommunications/Factor8and9/ Pharmacokinetic.asp. Accessed July 24, 2009.
23. Karlsson MO, Sheiner LB. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm. 1993;21(6):735-750. (Pubitemid 24052760)
24. Meibohm B, Läer S, Panetta JC, Barrett JS. Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J. 2005; 7(2):E475-E487. (Pubitemid 43071326)
25. Thomson AH, Whiting B. Bayesian parameter estimation and population pharmacokinetics. Clin Pharmacokinet. 1992;22(6):447-467.
26. Pillai G, Mentré F, Steimer JL. Non-linear mixed effects modeling: from methodology and software development to driving implementation in drug development science. J Pharmacokinet Pharmacodyn. 2005;32(2):161-183. (Pubitemid 41712738)
27. Food and Drug Administration. Guidance for industry: population pharmacokinetics. http:// www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/Guidances/ucm072137.pdf. Accessed March 17, 2011.
28. Karafoulidou A, Suarez E, Anastasopoulou I, et al. Population pharmacokinetics of recombinant factor VIII:C (ReFacto) in adult HIV-negative and HIV-positive haemophilia patients. Eur J Clin Pharmacol. 2009;65(11):1121-1130.
29. Holford NHG. A size standard for pharmacokinetics. Clin Pharmacokinet. 1996;30(5):329-332. (Pubitemid 26177179)
30. Björkman S, Folkesson A, Berntorp E. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting. Haemophilia. 2007;13(1):2-8. (Pubitemid 46002337)